Total Payments
$113,922
2024 Payments
$8,336
Companies
44
Transactions
1,267
Medicare Patients
5,174
Medicare Billing
$1.4M
Payment Breakdown by Category
Research$40,611 (35.6%)
Other$37,100 (32.6%)
Food & Beverage$15,610 (13.7%)
Consulting$15,340 (13.5%)
Travel$5,177 (4.5%)
Education$84.19 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $40,611 | 24 | 35.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,900 | 26 | 28.0% |
| Food and Beverage | $15,610 | 1,191 | 13.7% |
| Consulting Fee | $15,340 | 6 | 13.5% |
| Honoraria | $5,200 | 1 | 4.6% |
| Travel and Lodging | $5,177 | 13 | 4.5% |
| Education | $84.19 | 6 | 0.1% |
Payments by Type
General
$73,312
1,243 transactions
Research
$40,611
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $27,407 | 56 | $0 (2022) |
| Neurocrine Biosciences, Inc. | $21,056 | 81 | $0 (2022) |
| ACADIA Pharmaceuticals Inc | $13,873 | 6 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $12,470 | 57 | $0 (2024) |
| Ironshore Pharmaceuticals Inc. | $9,629 | 33 | $0 (2023) |
| Alkermes, Inc. | $9,558 | 177 | $0 (2024) |
| LivaNova USA, Inc. | $7,024 | 17 | $0 (2024) |
| Allergan, Inc. | $3,415 | 137 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $1,366 | 108 | $0 (2024) |
| AbbVie Inc. | $1,220 | 88 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,336 | 132 | LivaNova USA, Inc. ($6,679) |
| 2023 | $3,293 | 218 | Corium, LLC ($702.97) |
| 2022 | $2,967 | 235 | ABBVIE INC. ($572.57) |
| 2021 | $1,627 | 120 | AbbVie Inc. ($366.90) |
| 2020 | $227.03 | 16 | Allergan, Inc. ($55.54) |
| 2019 | $26,800 | 189 | Ironshore Pharmaceuticals Inc. ($9,403) |
| 2018 | $21,578 | 179 | Neurocrine Biosciences, Inc. ($15,001) |
| 2017 | $49,095 | 178 | Sunovion Pharmaceuticals Inc. ($26,925) |
All Payment Transactions
1,267 individual payment records from CMS Open Payments — Page 1 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $10.33 | General |
| Category: CNS | ||||||
| 12/18/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: NEUROLOGY | ||||||
| 12/18/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $3.68 | General |
| Category: CNS | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: PSYCHIATRY | ||||||
| 12/08/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: ANTI-ANXIETY | ||||||
| 12/03/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $10.84 | General |
| Category: CNS | ||||||
| 12/02/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $21.64 | General |
| Category: Narcoplepsy | ||||||
| 11/25/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Central Nervous System | ||||||
| 11/25/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 11/25/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $0.64 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 11/21/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: CNS | ||||||
| 11/20/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: NEUROLOGY | ||||||
| 11/07/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $11.13 | General |
| Category: Narcoplepsy | ||||||
| 11/06/2024 | Noven Therapeutics, LLC | Xelstrym (Drug), Secuado | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: ADHD | ||||||
| 11/05/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 11/05/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $0.72 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 11/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: NEUROLOGY | ||||||
| 11/03/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $30.23 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/31/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: CNS | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $18.60 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/28/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $9.96 | General |
| Category: CNS | ||||||
| 10/24/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $2.48 | General |
| Category: CNS | ||||||
| 10/21/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DASOTRALINE BINGE EATING DISORDER STUDY | Sunovion Pharmaceuticals Inc. | $11,262 | 2 |
| DASOTRALINE BINGE EATING DISORDER EXTENSION STUDY | Sunovion Pharmaceuticals Inc. | $10,662 | 16 |
| ACP-103-035 | ACADIA Pharmaceuticals Inc | $7,050 | 2 |
| ACP-103-038 | ACADIA Pharmaceuticals Inc | $5,800 | 1 |
| A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder | Sunovion Pharmaceuticals Inc. | $4,837 | 2 |
| ACP-103-034 | ACADIA Pharmaceuticals Inc | $1,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 589 | 2,425 | $538,244 | $174,910 |
| 2022 | 14 | 888 | 3,453 | $861,396 | $260,480 |
| 2021 | 16 | 1,013 | 3,882 | $1.3M | $330,592 |
| 2020 | 20 | 2,684 | 8,475 | $2.8M | $679,996 |
Total Patients
5,174
Total Services
18,235
Medicare Billing
$1.4M
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 357 | 1,723 | $441,290 | $146,942 | 33.3% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 54 | 58 | $22,875 | $7,458 | 32.6% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 31 | 187 | $23,936 | $5,796 | 24.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 31 | 187 | $23,936 | $5,531 | 23.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 26 | $7,885 | $3,033 | 38.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $7,100 | $2,575 | 36.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 24 | $3,800 | $1,293 | 34.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 18 | 126 | $5,112 | $1,239 | 24.2% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 36 | 77 | $2,310 | $1,044 | 45.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 434 | 2,002 | $400,400 | $168,187 | 42.0% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 16 | 374 | $224,400 | $41,445 | 18.5% |
| 90869 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent motor threshold redetermination with delivery and management | Office | 2022 | 16 | 81 | $97,200 | $8,909 | 9.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 51 | 219 | $28,032 | $8,157 | 29.1% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 51 | 219 | $28,032 | $7,606 | 27.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 42 | 51 | $14,120 | $6,728 | 47.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 40 | 40 | $14,800 | $5,980 | 40.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 54 | 78 | $11,700 | $4,592 | 39.2% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2022 | 15 | 18 | $21,600 | $2,539 | 11.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $7,830 | $2,271 | 29.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 32 | 182 | $7,384 | $1,766 | 23.9% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2022 | 57 | 101 | $3,030 | $1,427 | 47.1% |
| 92552 | Test for hearing various pitches using earphone | Office | 2022 | 17 | 25 | $1,500 | $609.12 | 40.6% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2022 | 36 | 36 | $1,368 | $264.74 | 19.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 388 | 1,774 | $354,800 | $159,321 | 44.9% |
| 90868 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), subsequent delivery and management, per session | Office | 2021 | 33 | 846 | $507,600 | $92,012 | 18.1% |
About Dr. Walter Duffy, MD
Dr. Walter Duffy, MD is a Psychiatry healthcare provider based in Lincoln, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1093853368.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Walter Duffy, MD has received a total of $113,922 in payments from pharmaceutical and medical device companies, with $8,336 received in 2024. These payments were reported across 1,267 transactions from 44 companies. The most common payment nature is "" ($40,611).
As a Medicare-enrolled provider, Duffy has provided services to 5,174 Medicare beneficiaries, totaling 18,235 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Child & Adolescent Psychiatry
- Location Lincoln, NE
- Active Since 02/01/2007
- Last Updated 09/12/2008
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1093853368
Products in Payments
- DASOTRALINE (Drug) $26,761
- INGREZZA (Drug) $21,056
- NUPLAZID (Drug) $13,873
- AUSTEDO (Drug) $11,700
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $9,403
- VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) $6,800
- VRAYLAR (Drug) $4,540
- ARISTADA (Drug) $1,299
- CAPLYTA (Drug) $1,093
- Azstarys (Drug) $949.50
- REXULTI (Drug) $877.50
- INVEGA SUSTENNA (Drug) $717.64
- XYWAV (Drug) $663.56
- LATUDA (Drug) $646.79
- QELBREE (Drug) $597.60
- SD809-TD (Drug) $586.10
- ABILIFY MAINTENA (Drug) $477.72
- WAKIX (Drug) $344.99
- VYVANSE (Drug) $241.12
- JORNAY PM (Drug) $226.08
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Lincoln
Dr. James Whalen, M.d, M.D
Psychiatry — Payments: $22,244
Psychiatry $22,244
Dianna Clyne, M.d, M.D
Psychiatry — Payments: $18,948
Psychiatry $18,948
Jeffrey Coffman, M.d, M.D
Psychiatry — Payments: $17,744
Psychiatry $17,744
Kelli Bremer, M.d, M.D
Psychiatry — Payments: $12,411
Psychiatry $12,411
Dr. Heather Abrahams, Md, MD
Psychiatry — Payments: $8,829
Psychiatry $8,829
Rajeev Chaturvedi, M.d, M.D
Psychiatry — Payments: $6,449
Psychiatry $6,449